Nanobac Pharmaceuticals Profit Margin

The latest profit margin for NNBP is -37319.74% as of December 2007. That compares with -2209.53% in the prior-year period — down 1589.0% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Nanobac Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, NNBP's profit margin moved from -2209.53% to -37319.74% — a 1589.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nanobac Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, NNBP currently prints -37319.74% for profit margin, while the sector average sits near 13.89%. That is roughly 268777.5% below the sector mean. Large gaps often invite a closer look at Nanobac Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Nanobac Pharmaceuticals converts resources into returns. At -37319.74%, NNBP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2209.53% in the prior-year period — down 1589.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NNBP's profit margin (-37319.74%), review year-over-year change from -2209.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.